{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:46:24Z","timestamp":1792791984689,"version":"4.5.0"},"reference-count":72,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.3594","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T15:31:54Z","timestamp":1617204714000},"page":"e213594","source":"Crossref","is-referenced-by-count":116,"title":["Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19"],"prefix":"10.1001","volume":"4","author":[{"given":"Ranu","family":"Baral","sequence":"first","affiliation":[{"name":"Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom"},{"name":"Department of Cardiology, Norwich Medical School, University of East Anglia, Norwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Tsampasian","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Debski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Moran","sequence":"additional","affiliation":[{"name":"National Health Service 111 COVID-19 Clinical Assessment Service, Bicester, United Kingdom"},{"name":"Neasden Medical Centre, London, United Kingdom"},{"name":"Healix International, Esher, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom"},{"name":"Department of Cardiology, Norwich Medical School, University of East Anglia, Norwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, Norwich Medical School, University of East Anglia, Norwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios S.","family":"Vassiliou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom"},{"name":"Department of Cardiology, Norwich Medical School, University of East Anglia, Norwich, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"issue":"7","key":"zoi210134r2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","article-title":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19).","volume":"5","author":"Guo","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"5","key":"zoi210134r3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s00392-020-01626-9","article-title":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.","volume":"109","author":"Li","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"zoi210134r4","author":"Feng"},{"issue":"8","key":"zoi210134r5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1080\/10641963.2020.1783549","article-title":"Is the use of ACE inb\/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?","volume":"42","author":"Selcuk","year":"2020","journal-title":"Clin Exp Hypertens"},{"issue":"9","key":"zoi210134r6","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1001\/jamacardio.2020.1855","article-title":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19).","volume":"5","author":"Mehta","year":"2020","journal-title":"JAMA Cardiol"},{"key":"zoi210134r7","author":"Bravi","year":"2020"},{"issue":"7","key":"zoi210134r8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1080\/10641963.2020.1764018","article-title":"Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors.","volume":"42","author":"Zhou","year":"2020","journal-title":"Clin Exp Hypertens"},{"issue":"10","key":"zoi210134r9","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/ajh\/hpaa096","article-title":"Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives.","volume":"33","author":"Felice","year":"2020","journal-title":"Am J Hypertens"},{"key":"zoi210134r10","author":"Zhou"},{"issue":"10","key":"zoi210134r11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11883-020-00880-6","article-title":"Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients.","volume":"22","author":"Baral","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"zoi210134r13","author":"Wu"},{"key":"zoi210134r15","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"zoi210134r16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v049.i05","article-title":"Closing the gap between methodologists and end-users: R as a computational back-end.","volume":"49","author":"Wallace","year":"2012","journal-title":"J Stat Softw"},{"issue":"3","key":"zoi210134r18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jacc.2020.05.040","article-title":"Ramipril in high-risk patients with COVID-19.","volume":"76","author":"Amat-Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"zoi210134r19","author":"Conversano"},{"key":"zoi210134r20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.amjcard.2020.07.007","article-title":"Angiotensin converting enzyme inhibitor and angiotensin II receptor blocker use among outpatients diagnosed with COVID-19.","volume":"132","author":"Bae","year":"2020","journal-title":"Am J Cardiol"},{"issue":"6","key":"zoi210134r21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/ejhf.v22.6","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.","volume":"22","author":"Bean","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"zoi210134r22","author":"Cannata"},{"issue":"21","key":"zoi210134r23","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017736","article-title":"Mortality and pre-hospitalization use of renin-angiotensin system inhibitors in hypertensive COVID-19 patients.","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"zoi210134r24","year":"2020"},{"issue":"7","key":"zoi210134r25","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/dc20-0660","article-title":"Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication.","volume":"43","author":"Chen","year":"2020","journal-title":"Diabetes Care"},{"issue":"19","key":"zoi210134r26","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1136\/heartjnl-2020-317393","article-title":"Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.","volume":"106","author":"Hippisley-Cox","year":"2020","journal-title":"Heart"},{"key":"zoi210134r27","author":"Fosbol","year":"2020"},{"issue":"22","key":"zoi210134r28","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study.","volume":"41","author":"Gao","year":"2020","journal-title":"Eur Heart J"},{"key":"zoi210134r29","doi-asserted-by":"crossref","DOI":"10.1038\/s41371-020-00405-3","article-title":"Association between renin-angiotensin-aldosterone system inhibitor treatment, neutrophil-lymphocyte ratio, D-dimer and clinical severity of COVID-19 in hospitalized patients: a multicenter, observational study.","author":"Gormez","year":"2020","journal-title":"J Hum Hypertens"},{"key":"zoi210134r30","author":"Grasselli"},{"key":"zoi210134r31","author":"Guo"},{"issue":"7","key":"zoi210134r32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.21037\/atm","article-title":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension.","volume":"8","author":"Huang","year":"2020","journal-title":"Ann Transl Med"},{"issue":"9","key":"zoi210134r33","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s10072-020-04541-z","article-title":"Neurological diseases as mortality predictive factors for patients with COVID-19: a retrospective cohort study.","volume":"41","author":"Hwang","year":"2020","journal-title":"Neurol Sci"},{"key":"zoi210134r34","author":"Iaccarino"},{"key":"zoi210134r35","author":"Jung","year":"2021"},{"issue":"16","key":"zoi210134r36","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1093\/cid\/ciaa624","article-title":"Association of renin-angiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19)\u2013related outcomes in Korea: a nationwide population-based cohort study.","volume":"71","author":"Jung","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"zoi210134r37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/0036933020951926","article-title":"Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease: a multi-centre observational study.","volume":"65","author":"Khan","year":"2020","journal-title":"Scott Med J"},{"issue":"8","key":"zoi210134r38","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/infdis\/jiaa447","article-title":"Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome.","volume":"222","author":"Lam","year":"2020","journal-title":"J Infect Dis"},{"issue":"7","key":"zoi210134r39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China.","volume":"5","author":"Li","year":"2020","journal-title":"JAMA Cardiol"},{"key":"zoi210134r40","author":"Liabeuf","year":"2020"},{"key":"zoi210134r41","author":"Liu"},{"key":"zoi210134r42","author":"Lopez-Otero","year":"2020"},{"key":"zoi210134r43","author":"Mancia"},{"issue":"11","key":"zoi210134r44","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41440-020-00535-8","article-title":"Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.","volume":"43","author":"Matsuzawa","year":"2020","journal-title":"Hypertens Res"},{"issue":"1","key":"zoi210134r45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"zoi210134r46","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2020.104204","article-title":"Clinical course and prognostic factors of COVID-19 infection in an elderly hospitalized population.","volume":"91","author":"Mostaza","year":"2020","journal-title":"Arch Gerontol Geriatr"},{"key":"zoi210134r47","author":"Oussalah","year":"2020"},{"key":"zoi210134r48","author":"Pan"},{"issue":"25","key":"zoi210134r49","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","article-title":"Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19.","volume":"382","author":"Reynolds","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi210134r50","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"zoi210134r51","author":"Rossi","year":"2020"},{"issue":"17","key":"zoi210134r52","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016948","article-title":"Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? data from centers of southern Italy.","volume":"9","author":"Sardu","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"zoi210134r53","first-page":"21","article-title":"Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.","volume":"24","author":"Senkal","year":"2020","journal-title":"Anatol J Cardiol"},{"issue":"12","key":"zoi210134r54","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1097\/HJH.0000000000002584","article-title":"Baseline use of angiotensin-converting enzyme inhibitor\/AT1 blocker and outcomes in hospitalized coronavirus disease 2019 African-American patients.","volume":"38","author":"Shah","year":"2020","journal-title":"J Hypertens"},{"issue":"3","key":"zoi210134r55","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","article-title":"Associations between angiotensin-converting enzyme inhibitors and angiotensin II receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19.","volume":"159","author":"Tan","year":"2020","journal-title":"Gastroenterology"},{"issue":"15","key":"zoi210134r56","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/cid\/ciaa492","article-title":"Clinical impact of renin-angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for coronavirus disease 2019.","volume":"71","author":"Tedeschi","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"zoi210134r57","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40264-020-00994-5","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43,000 patients.","volume":"43","author":"Trifiro","year":"2020","journal-title":"Drug Saf"},{"issue":"5","key":"zoi210134r58","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11684-020-0800-y","article-title":"Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.","volume":"14","author":"Xu","year":"2020","journal-title":"Front Med"},{"key":"zoi210134r59","author":"Yang"},{"key":"zoi210134r60","author":"Yuan","year":"2020"},{"key":"zoi210134r61","author":"Zhang"},{"issue":"6","key":"zoi210134r62","first-page":"450","article-title":"[Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV].","volume":"48","author":"Peng","year":"2020","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"10238","key":"zoi210134r63","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"zoi210134r64","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.jinf.2020.05.056","article-title":"COVID-19 is more severe in patients with hypertension; ACEI\/ARB treatment does not influence clinical severity and outcome.","volume":"81","author":"Hu","year":"2020","journal-title":"J Infect"},{"key":"zoi210134r65","article-title":"Role of drugs affecting the renin-angiotensin-aldosterone system on susceptibility and severity of COVID-19: a large case-control study from Zheijang Province, China.","author":"Yan"},{"issue":"19","key":"zoi210134r66","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1093\/eurheartj\/ehaa231","article-title":"Coronaviruses and the cardiovascular system: acute and long-term implications.","volume":"41","author":"Xiong","year":"2020","journal-title":"Eur Heart J"},{"issue":"6","key":"zoi210134r67","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1111\/jcpt.v45.6","article-title":"Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: a systematic review and meta-analysis.","volume":"45","author":"Barochiner","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"zoi210134r68","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/cvr\/cvaa097","article-title":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19.","volume":"116","author":"Kreutz","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"1","key":"zoi210134r69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpu086","article-title":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.","volume":"28","author":"Furuhashi","year":"2015","journal-title":"Am J Hypertens"},{"key":"zoi210134r1","unstructured":"World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Updated February 13, 2021. Accessed January 18, 2021. https:\/\/covid19.who.int\/"},{"key":"zoi210134r12","doi-asserted-by":"crossref","unstructured":"World Health Organization. COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers: scientific brief. May 7, 2020. Accessed October 20, 2020. https:\/\/www.who.int\/news-room\/commentaries\/detail\/covid-19-and-the-use-of-angiotensin-converting-enzyme-inhibitors-and-receptor-blockers","DOI":"10.15557\/PiMR.2020.0023"},{"key":"zoi210134r14","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute; 2019. Accessed October 20, 2020. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"zoi210134r17","unstructured":"Higgins? JPT, Li? T, Deeks? JJ. Chapter 6: choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1. Cochrane; 2020. Accessed October 20, 2020. https:\/\/training.cochrane.org\/handbook\/current\/chapter-06"},{"key":"zoi210134r70","unstructured":"de Simone G. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. European Society of Cardiology; 2020. Accessed May 25, 2020. https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang"},{"key":"zoi210134r71","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Kovacs R, Harrington B. HFSA\/ACC\/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. American College of Cardiology; 2020. Accessed May 3, 2020. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19","DOI":"10.1016\/j.cardfail.2020.04.013"},{"key":"zoi210134r72","unstructured":"Kreutz R, Januszewicz A. Letter on the COVID-19 pandemic from the president of the European Society of Hypertension. April 7, 2020. Accessed May 25, 2020. https:\/\/www.eshonline.org\/esh-content\/uploads\/2020\/06\/ESH-LETTER-COVID-19-by-ESH-President-and-Secretary-April-7-2020.pdf?"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2777978\/baral_2021_oi_210134_1616524184.60142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T01:18:01Z","timestamp":1671758281000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2777978"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3594","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]}}}